Show simple item record

dc.contributor.authorPowell, C
dc.contributor.authorNewbold, K
dc.contributor.authorHarrington, KJ
dc.contributor.authorBhide, SA
dc.contributor.authorNutting, CM
dc.date.accessioned2018-06-05T14:31:44Z
dc.date.issued2010-08
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2010, 22 (6), pp. 456 - 463
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1720
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2010.03.012
dc.description.abstractThe management of differentiated thyroid cancer involves a combination of surgery, thyroid stimulating hormone suppression and radioactive iodine for most patients. In a small subset of patients, external beam radiotherapy is also used. However, its role remains controversial and there are no randomised controlled trials to guide practice. In this overview we review the evidence from the published literature for the use of external beam radiotherapy in the management of differentiated thyroid cancer and discuss the indications for which it is most commonly used. The technique of external beam radiotherapy, including the emerging role for intensity-modulated radiotherapy, will also be discussed.
dc.formatPrint-Electronic
dc.format.extent456 - 463
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectThyroid Neoplasms
dc.subjectTreatment Outcome
dc.subjectRadiotherapy, Adjuvant
dc.subjectRadiotherapy, Conformal
dc.subjectRadiotherapy, Intensity-Modulated
dc.titleExternal beam radiotherapy for differentiated thyroid cancer.
dc.typeJournal Article
dcterms.dateAccepted2010-03-22
rioxxterms.versionofrecord10.1016/j.clon.2010.03.012
rioxxterms.licenseref.startdate2010-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume22
pubs.embargo.termsNot known
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorNutting, Chrisen
dc.contributor.icrauthorBhide, Shreerangen
dc.contributor.icrauthorNewbold, Kateen
dc.contributor.icrauthorHarrington, Kevinen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record